Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Ontology highlight
ABSTRACT: This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled.
LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.
DISEASE(S): Ovarian Cancer,Colorectal, Ovarian, Pancreatic, Gallbladder And Bile Duct Cancer,Pancreatic Adenocarcinoma,Colorectal Cancer,Cancer,Biliary Carcinoma
PROVIDER: 2249969 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA